Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 13, 2016
Zacks Investment Research has downgraded Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to Hold in a statement released on 10/13/2016.
On 9/30/2016, Brean Capital released a statement on Alder Biopharmaceuticals Inc (NASDAQ:ALDR) upped the target price from $0.00 to $45.00 that suggested an upside of 0.44%.
Having a price of $28.18, Alder Biopharmaceuticals Inc (NASDAQ:ALDR) traded -0.95% lower on the day. With the last close down -1.93% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Alder Biopharmaceuticals Inc has recorded a 50-day average of $32.00 and a two hundred day average of $28.73. Volume of trade was up over the average, with 652,223 shares of ALDR changing hands over the typical 544,318
With a total market value of $0, Alder Biopharmaceuticals Inc has with a one year low of $15.82 and a one year high of $39.43 .
A total of 4 analysts have released a research note on Alder Biopharmaceuticals Inc. Two analysts rating the company a strong buy, one analyst rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $47.00.
More About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.